Background to 2022
I’ve only ever sent these on Facebook but this year, after some challenges, I wanted to make sure I covered anyone who supports my sites via one channel whether it is Twitter, Facebook, Newsletter or direct from a subscription to my website. All of the outlets above have kept my viewing figures high, I guess I can’t complain about a 2022 total of around 270,000 blog hits and hitting the milestone of 2 million blog hits in early November – that was a major boost. It takes 3-4 years to get a million hits based on current performance.
This has been a challenging year, mainly because the pandemic had some impact on my social media activity and also in terms of growth. 2020 and 2021 were slower than normal but 2022 has seen some pickup. At the time of writing my annual blog figures are higher than in 2021 so hopefully a reversal of the downward trend seen during the pandemic. Some of it is due to less writing but much is due to a change in Facebook algorithms which affected many ‘pages’ reducing their scope (the more cynical might say it was done to drive advertising revenue but …….). My page “Neuroendocrine Cancer” was badly hit by this algorithm change but things are slowly improving. There is a long way to go still as I can’t work out whether the page is less supported, or the algorithm doesn’t work for the current content. Using Facebook ads to improve hits has turned out to be hit-and-miss. I’m reviewing that. Running my “Ronny Allan” Facebook page takes a lot of effort, but I get a lot of satisfaction from doing it. My new awareness page World Neuroendocrine Cancer Day is growing steadily.
One of my biggest challenges was managing my private Facebook group – this is a big draw on my time and something I didn’t have in the first few years of my blog. I get busier as it gets bigger. With almost 8000 members, it is now the biggest Neuroendocrine Cancer Facebook group in the world. That was not my mission, it just happened!
My newsletter has been very successful using the Revue tool provided by Twitter. It was one of the easiest apps I have ever used and was quick to produce. However (and sadly), they will be closing that feature on 16th Jan 2023, most likely due to reorganisation within Twitter which you may have seen in the news. I will resurrect my old newsletter app and import the subscribers in due course. In the meantime, if you want your email to be ported to the new newsletter system, please subscribe to the current newsletter before 16 Jan 2023 to be included. Click here to subscribe.
OK, enough of that ‘techie’ social media stuff! I mainly wanted to thank you for supporting me throughout 2022. Without you guys reading my blog, liking and commenting on my newsletters and Facebook posts; and joining and asking questions in my private Facebook group, life might be boring and quiet. I would also like to thank those on my public Facebook pages for their support for Chris too. She is really integrated into many of the posts on my “Ronny Allan” page and provides many pictures and story ideas.
Please be careful over the Christmas and New Year holiday periods and have a great time. The private group will continue to function 24/7 and will not be paused. My pages and blog site may be quieter than normal.
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
What is Carcinoid Syndrome? Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine